Context Therapeutics Inc.
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
CNTX | US
Overview
Corporate Details
- ISIN(s):
- US21077P1084
- LEI:
- Country:
- United States of America
- Address:
- 2001 MARKET STREET, 19103 PHILADELPHIA
- Sector:
- Manufacturing
Description
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to advancing treatments for solid tumors. The company develops next-generation T cell engaging (TCE) bispecific antibody therapies designed to harness the patient's immune system for targeted cancer eradication. Its pipeline features innovative immunotherapeutic solutions for difficult-to-treat solid tumors. Key portfolio highlights include CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody; CT-95, an avidity-enhanced mesothelin (MSLN) x CD3 bispecific antibody; and CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific antibody.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Context Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Context Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Context Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
